| Aggrecan |
PDB rendering based on 1tdq. |
| Identifiers |
| Symbols |
ACAN; AGC1; AGCAN; CSPG1; CSPGCP; MSK16; SEDK |
| External IDs |
OMIM: 155760 HomoloGene: 7227 GeneCards: ACAN Gene |
| Gene Ontology |
| Molecular function |
• extracellular matrix structural constituent
• protein binding
• hyaluronic acid binding
• metal ion binding
|
| Cellular component |
• proteinaceous extracellular matrix
• extracellular matrix
|
| Biological process |
• skeletal system development
• proteolysis
• cell adhesion
|
| Sources: Amigo / QuickGO |
|
| RNA expression pattern |
|
|
|
| More reference expression data |
| Orthologs |
| Species |
Human |
Mouse |
|
| Entrez |
176 |
11595 |
|
| Ensembl |
ENSG00000157766 |
ENSMUSG00000030607 |
|
| UniProt |
P16112 |
Q61282 |
|
| RefSeq (mRNA) |
NM_001135.3 |
NM_007424.2 |
|
| RefSeq (protein) |
NP_001126.3 |
NP_031450.2 |
|
| Location (UCSC) |
Chr 15:
89.35 – 89.42 Mb |
Chr 7:
86.2 – 86.26 Mb |
|
| PubMed search |
[1] |
[2] |
|
|
|
Aggrecan also known as cartilage-specific proteoglycan core protein (CSPCP) or chondroitin sulfate proteoglycan 1 is a protein that in humans is encoded by the ACAN gene.[1] This gene is a member of the aggrecan/versican proteoglycan family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage.
Aggrecan is a proteoglycan, or a protein modified with large carbohydrates; the human form of the protein is 2316 amino acids long and can be expressed in multiple isoforms due to alternative splicing.[1]
|
Contents
- 1 Structure
- 2 Function
- 3 Clinical significance
- 4 Interactions
- 5 References
- 6 Further reading
- 7 External links
|
Structure
Aggrecan is a high molecular weight (1x106 < M < 3x106) proteoglycan. It exhibits a bottlebrush structure, in which chondroitin sulfate and keratan sulfate chains are attached to an extended protein core.[2]
Aggrecan has a molecular mass >2,500 kDa. The core protein (210–250 kDa) has 100–150 glycosaminoglycan (GAG) chains attached to it. Along with type-II collagen, aggrecan forms a major structural component of cartilage, particularly articular cartilage. Aggrecan consists of two globular structural domains at the N-terminal end and one globular domain at the C-terminal end, separated by a large domain heavily modified with glycosaminoglycans. The two main modifier moieties are themselves arranged into distinct regions, a chondroitin sulfate and a keratan sulfate region. It contains three globular domains, G1, G2, and G3 that are involved in aggregation, hyaluronan binding, cell adhesion, and chondrocyte apoptosis. A large extended region (CS) between G2 and G3 for glycosaminoglycan chain attachment. G1 comprises the amino terminus of the core protein.
The aggrecan family includes other important members such as versican, also named PG-M, neurocan, brevican and the cell surface HA receptor CD44. They are modular proteoglycans containing combinations of structural motifs, such as EGF-like domains, carbohydrate recognition domains (CRD), complement binding protein (CBP)-like domains, immunoglobulin folds and proteoglycan tandem repeats.
Function
Aggrecan is a critical component for cartilage structure and the function of joints.
Functionally, the G1 domain interacts with hyaluronan acid and link protein, forming stable ternary complexes in the extracellular matrix. G2 is homologous to the tandem repeats of G1 and of link protein and is involved in product processing. G3 makes up the carboxyl terminus of the core protein. It enhances glycosaminoglycan modification and product secretion. Aggrecan plays an important role in mediating chondrocyte-chondrocyte and chondrocyte-matrix interactions through its ability to bind hyaluronan.[3]
Aggrecan provides intervertebral disc and cartilage with the ability to resist compressive loads. The localized high concentrations of aggrecan provide the osmotic properties necessary for normal tissue function with the GAGs producing the swelling pressure that counters compressive loads on the tissue. This functional ability is dependent on a high GAG/aggrecan concentration being present in the tissue extracellular matrix.[4]
Clinical significance
The synthesis and degradation of aggrecan are being investigated for their roles in cartilage deterioration during joint injury, disease, and aging.
The linker domain between the N-terminal globular domains, called the interglobular domain, is highly sensitive to proteolysis. Such degradation has been associated with the development of arthritis. Proteases capable of degrading aggrecans are called aggrecanases, and they are members of the ADAM (A Disintegrin And Metalloprotease) protein family.[5]
Degenerative joint disease is a leading source of morbidity resulting in significant social and economic impact. Osteoarthritis is characterized by the slow progressive deterioration of articular cartilage. Cartilage contains up to 10% proteoglycan consisting of mainly the large aggregating chondroitin sulfate proteoglycan aggrecan.
Interactions
Aggrecan has been shown to interact with versican.[6]
References
- ^ a b Doege KJ, Sasaki M, Kimura T, Yamada Y (January 1991). "Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms". J. Biol. Chem. 266 (2): 894–902. PMID 1985970.
- ^ Nap RJ, Szleifer I (November 2008). "Structure and interactions of aggrecans: statistical thermodynamic approach". Biophys. J. 95 (10): 4570–83. doi:10.1529/biophysj.108.133801. PMC 2576360. PMID 18689463. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2576360.
- ^ Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB (March 2002). "Structure and function of aggrecan". Cell Res. 12 (1): 19–32. doi:10.1038/sj.cr.7290106. PMID 11942407.
- ^ Roughley P, Martens D, Rantakokko J, Alini M, Mwale F, Antoniou J (2006). "The involvement of aggrecan polymorphism in degeneration of human intervertebral disc and articular cartilage". Eur Cell Mater 11: 1–7; discussion 7. PMID 16425147.
- ^ East CJ, Stanton H, Golub SB, Rogerson FM, Fosang AJ (2007). "ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan". J. Biol. Chem. 282 (12): 8632–40. doi:10.1074/jbc.M605750200. PMID 17255106.
- ^ Matsumoto K, Shionyu M, Go M, Shimizu K, Shinomura T, Kimata K, Watanabe H (October 2003). "Distinct interaction of versican/PG-M with hyaluronan and link protein". J. Biol. Chem. 278 (42): 41205–12. doi:10.1074/jbc.M305060200. PMID 12888576.
Further reading
- Watanabe H, Yamada Y, Kimata K (1999). "Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function.". J. Biochem. 124 (4): 687–93. PMID 9756610.
- Fosang AJ, Neame PJ, Last K, et al. (1992). "The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B.". J. Biol. Chem. 267 (27): 19470–4. PMID 1326552.
- Sandy JD, Flannery CR, Neame PJ, Lohmander LS (1992). "The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain.". J. Clin. Invest. 89 (5): 1512–6. doi:10.1172/JCI115742. PMC 443022. PMID 1569188. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=443022.
- Baldwin CT, Reginato AM, Prockop DJ (1989). "A new epidermal growth factor-like domain in the human core protein for the large cartilage-specific proteoglycan. Evidence for alternative splicing of the domain.". J. Biol. Chem. 264 (27): 15747–50. PMID 2789216.
- Kimata K, Barrach HJ, Brown KS, Pennypacker JP (1981). "Absence of proteoglycan core protein in cartilage from the cmd/cmd (cartilage matrix deficiency) mouse.". J. Biol. Chem. 256 (13): 6961–8. PMID 7240256.
- Glumoff V, Savontaus M, Vehanen J, Vuorio E (1994). "Analysis of aggrecan and tenascin gene expression in mouse skeletal tissues by northern and in situ hybridization using species specific cDNA probes.". Biochim. Biophys. Acta 1219 (3): 613–22. doi:10.1016/0167-4781(94)90220-8. PMID 7524681.
- Ilic MZ, Mok MT, Williamson OD, et al. (1995). "Catabolism of aggrecan by explant cultures of human articular cartilage in the presence of retinoic acid.". Arch. Biochem. Biophys. 322 (1): 22–30. doi:10.1006/abbi.1995.1431. PMID 7574678.
- Valhmu WB, Palmer GD, Rivers PA, et al. (1995). "Structure of the human aggrecan gene: exon-intron organization and association with the protein domains.". Biochem. J.. 309 ( Pt 2): 535–42. PMC 1135764. PMID 7626017. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1135764.
- Barry FP, Neame PJ, Sasse J, Pearson D (1995). "Length variation in the keratan sulfate domain of mammalian aggrecan.". Matrix Biol. 14 (4): 323–8. doi:10.1016/0945-053X(94)90198-8. PMID 7827755.
- Fosang AJ, Last K, Neame PJ, et al. (1995). "Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan.". Biochem. J.. 304 ( Pt 2): 347–51. PMC 1137499. PMID 7998967. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1137499.
- Fosang AJ, Last K, Knäuper V, et al. (1993). "Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.". Biochem. J.. 295 ( Pt 1): 273–6. PMC 1134849. PMID 8216228. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1134849.
- Korenberg JR, Chen XN, Doege K, et al. (1993). "Assignment of the human aggrecan gene (AGC1) to 15q26 using fluorescence in situ hybridization analysis.". Genomics 16 (2): 546–8. doi:10.1006/geno.1993.1228. PMID 8314595.
- Dudhia J, Davidson CM, Wells TM, et al. (1996). "Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage.". Biochem. J.. 313 ( Pt 3): 933–40. PMC 1217001. PMID 8611178. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1217001.
- Fülöp C, Cs-Szabó G, Glant TT (1996). "Species-specific alternative splicing of the epidermal growth factor-like domain 1 of cartilage aggrecan.". Biochem. J.. 319 ( Pt 3): 935–40. PMC 1217878. PMID 8921002. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1217878.
- Kirschfink M, Blase L, Engelmann S, Schwartz-Albiez R (1997). "Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.". J. Immunol. 158 (3): 1324–31. PMID 9013976.
- Parkar AA, Kahmann JD, Howat SL, et al. (1998). "TSG-6 interacts with hyaluronan and aggrecan in a pH-dependent manner via a common functional element: implications for its regulation in inflamed cartilage.". FEBS Lett. 428 (3): 171–6. doi:10.1016/S0014-5793(98)00523-7. PMID 9654129.
- Fosang AJ, Last K, Fujii Y, et al. (1998). "Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain.". FEBS Lett. 430 (3): 186–90. doi:10.1016/S0014-5793(98)00667-X. PMID 9688535.
- "Aggrecan". Learning Center. Sigma-Aldrich Company. http://www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/learning-center/structural-proteins/aggrecan.html. Retrieved 2011-10-24.
External links
- Aggrecan at the US National Library of Medicine Medical Subject Headings (MeSH)
|
PDB gallery
|
|
|
|
|
1tdq: Structural basis for the interactions between tenascins and the C-type lectin domains from lecticans: evidence for a cross-linking role for tenascins
|
|
|
|
|
Protein: lectins
|
|
| Animal |
|
C-type lectins
|
- Asialoglycoprotein receptor
- KLRD1
- Collectin
- Mannose receptor
- proteochondroitin sulfate
- Aggrecan
- Versican
- Brevican
- Neurocan
|
|
|
Other
|
- Calnexin
- Calreticulin
- CD22
- CD33
- Galectin
- Myelin-associated glycoprotein
- N-Acetylglucosamine receptor
- Selectin
- Sialoadhesin
|
|
|
| Plant |
- Abrin
- Ricin
- Mitogens
- Concanavalin A
- Phytohaemagglutinin
- Pokeweed mitogen
- Legume lectin
- BanLec
|
|
|
Protein, glycoconjugate: glycoproteins and glycopeptides
|
|
| Mucoproteins |
|
Mucin
|
CD43 · CD164 · MUC1 · MUC2 · MUC3A · MUC3B · MUC4 · MUC5AC · MUC5B · MUC6 · MUC7 · MUC8 · MUC12 · MUC13 · MUC15 · MUC16 · MUC17 · MUC19 · MUC20
|
|
|
Other
|
Haptoglobin · Intrinsic factor · Orosomucoid · Peptidoglycan · Phytohaemagglutinin · Ovomucin
|
|
|
| Proteoglycans |
|
CS/DS
|
Decorin · Biglycan · Versican
|
|
|
HS/CS
|
Testican · Perlecan
|
|
|
CS
|
Chondroitin sulfate proteoglycans: Aggrecan · Neurocan · Brevican · CD44 · CSPG4 · CSPG5 · Platelet factor 4 · Structural maintenance of chromosomes 3
|
|
|
KS
|
Fibromodulin · Lumican · Keratocan
|
|
|
HS
|
Syndecan 1
|
|
|
| Other |
Activin and inhibin · ADAM · Alpha 1-antichymotrypsin · Apolipoprotein H · CD70 · Asialoglycoprotein · Avidin · B-cell activating factor · 4-1BB ligand · Cholesterylester transfer protein · Clusterin · Colony-stimulating factor · Hemopexin · Lactoferrin · Membrane glycoproteins · Myelin protein zero · Osteonectin · Protein C · Protein S · Serum amyloid P component · Sialoglycoprotein (CD43, Glycophorin, Glycophorin C) · Thrombopoietin · Thyroglobulin · Thyroxine-binding proteins · Transcortin · Tumor necrosis factor-alpha · Uteroglobin · Vitronectin
|
|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m(A16/C10),i(k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
biochemical families: proteins (amino acids/intermediates) · nucleic acids (constituents/intermediates) · carbohydrates (glycoproteins, alcohols, glycosides)
lipids (fatty acids/intermediates, phospholipids, steroids, sphingolipids, eicosanoids) · tetrapyrroles/intermediates
|
|
